Fig. 2From: Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III studyMean a GH and b standardized IGF-1 levels at extension baseline and after crossover. The n numbers refer to the number of patients with available data at each month. Oct, octreotide; Pas, pasireotide; SD, standard deviationBack to article page